Tyra Biosciences, Inc.

NasdaqGS TYRA

Tyra Biosciences, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -100.09 M

Tyra Biosciences, Inc. EBIT is USD -100.09 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -44.38% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Tyra Biosciences, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -69.33 M, a -28.76% change year over year.
Tyra Biosciences, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -53.84 M, a -168.23% change year over year.
Tyra Biosciences, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -20.07 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGS: TYRA

Tyra Biosciences, Inc.

CEO	Dr. Todd Harris Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	2656 State Street
Employees	49
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Key trends

Past 5 years